pioglitazone has been researched along with Psoriasis in 16 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS." | 9.22 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). ( Bhansali, A; Singh, S, 2016) |
| "To evaluate the therapeutic efficacy of pioglitazone on psoriasis vulgaris and its comorbidities." | 9.20 | Clinical effects of "pioglitazone", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. ( Abdel Halim, MR; Bosseila, M; Hafez, VG; Kamal, M; Kareem, HS; Shaker, OG, 2015) |
| "To evaluate the efficacy and safety of combination therapy with acitretin and pioglitazone hydrochloride in patients with moderate to severe chronic plaque-type psoriasis." | 9.14 | Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. ( Dogra, S; Kaur, I; Malhotra, S; Mittal, R; Pandhi, P, 2009) |
| "In a 10-week, double-blind, randomized, placebo-controlled, parallel-group study, 70 patients with moderate to severe psoriasis received one of the following treatments: pioglitazone 15 mg, pioglitazone 30 mg or placebo." | 9.11 | Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). ( Gupta, M; Kumar, B; Malhotra, S; Pandhi, P; Sandhu, K; Shafiq, N, 2005) |
| "Pioglitazone may be beneficial in the treatment of psoriasis." | 9.05 | Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials. ( Ding, Y; Guan, MM; Kang, XJ; Xiang, F; Yu, SR; Zhang, DZ; Zhang, JZ, 2020) |
| "Pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis, but its role in the treatment of psoriasis remains in debate." | 9.05 | The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials. ( Chen, P; Chen, X; Lei, L; Lv, J; Xiang, J; Zhang, Y; Zhou, J, 2020) |
| "Single centre, parallel group, randomized, study of metformin, pioglitazone and placebo in psoriasis patients with MS." | 5.22 | Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). ( Bhansali, A; Singh, S, 2016) |
| "To evaluate the therapeutic efficacy of pioglitazone on psoriasis vulgaris and its comorbidities." | 5.20 | Clinical effects of "pioglitazone", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. ( Abdel Halim, MR; Bosseila, M; Hafez, VG; Kamal, M; Kareem, HS; Shaker, OG, 2015) |
| "To evaluate the efficacy and safety of combination therapy with acitretin and pioglitazone hydrochloride in patients with moderate to severe chronic plaque-type psoriasis." | 5.14 | Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. ( Dogra, S; Kaur, I; Malhotra, S; Mittal, R; Pandhi, P, 2009) |
| "The current evidence demonstrates therapeutic efficacy of pioglitazone, which may be a treatment option in patients with psoriasis and diabetes mellitus." | 5.12 | Effects of antidiabetic drugs on psoriasis: A meta-analysis. ( Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH, 2021) |
| "In a 10-week, double-blind, randomized, placebo-controlled, parallel-group study, 70 patients with moderate to severe psoriasis received one of the following treatments: pioglitazone 15 mg, pioglitazone 30 mg or placebo." | 5.11 | Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). ( Gupta, M; Kumar, B; Malhotra, S; Pandhi, P; Sandhu, K; Shafiq, N, 2005) |
| "Pioglitazone may be beneficial in the treatment of psoriasis." | 5.05 | Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials. ( Ding, Y; Guan, MM; Kang, XJ; Xiang, F; Yu, SR; Zhang, DZ; Zhang, JZ, 2020) |
| "Pioglitazone may have potential benefits in the treatment of cutaneous and metabolic derangements of psoriasis, but its role in the treatment of psoriasis remains in debate." | 5.05 | The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials. ( Chen, P; Chen, X; Lei, L; Lv, J; Xiang, J; Zhang, Y; Zhou, J, 2020) |
| "After treatment of psoriasis patients with a traditional anti-psoriatic drug in combination with metformin and peroxisome proliferator-activated receptor gamma (PPARɤ) agonist (pioglitazone), the CD4+ T cells, IL-2, CRP, CP, ALT and AST levels were statistically significantly decreased compared to psoriasis patients without treatment." | 3.85 | Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis. ( Ahmed, AS; Al-Najjar, AH; El-Gharabawy, RM, 2017) |
| " Rosiglitazone and pioglitazone are being evaluated for the treatment of psoriasis." | 3.73 | Type 2 diabetes, psoriasis and thiazolidinediones. ( Friedmann, PS; Krentz, AJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, X | 1 |
| Meng, X | 1 |
| Song, Z | 1 |
| Lin, J | 1 |
| Zhang, JZ | 1 |
| Ding, Y | 1 |
| Xiang, F | 1 |
| Yu, SR | 1 |
| Zhang, DZ | 1 |
| Guan, MM | 1 |
| Kang, XJ | 1 |
| Chen, P | 1 |
| Chen, X | 1 |
| Lei, L | 1 |
| Zhang, Y | 1 |
| Xiang, J | 1 |
| Zhou, J | 1 |
| Lv, J | 1 |
| Chi, CC | 1 |
| Lee, CY | 1 |
| Liu, CY | 1 |
| Wang, SH | 1 |
| Tien O'Donnell, F | 1 |
| Tung, TH | 1 |
| Ghiasi, M | 1 |
| Ebrahimi, S | 1 |
| Lajevardi, V | 2 |
| Taraz, M | 1 |
| Azizpour, A | 1 |
| Chang, G | 1 |
| Wang, J | 1 |
| Song, J | 1 |
| Zhang, Z | 1 |
| Zhang, L | 1 |
| Hafez, VG | 1 |
| Bosseila, M | 1 |
| Abdel Halim, MR | 1 |
| Shaker, OG | 1 |
| Kamal, M | 1 |
| Kareem, HS | 1 |
| Hallaji, Z | 1 |
| Daklan, S | 1 |
| Abedini, R | 1 |
| Goodarzi, A | 1 |
| Abdolreza, M | 1 |
| Singh, S | 1 |
| Bhansali, A | 1 |
| El-Gharabawy, RM | 1 |
| Ahmed, AS | 1 |
| Al-Najjar, AH | 1 |
| Mittal, R | 1 |
| Malhotra, S | 2 |
| Pandhi, P | 2 |
| Kaur, I | 1 |
| Dogra, S | 1 |
| Itoh, S | 1 |
| Kanazuka, A | 1 |
| Akimoto, T | 1 |
| Bhagavathula, N | 1 |
| Nerusu, KC | 1 |
| Lal, A | 1 |
| Ellis, CN | 1 |
| Chittiboyina, A | 1 |
| Avery, MA | 1 |
| Ho, CI | 1 |
| Benson, SC | 1 |
| Pershadsingh, HA | 1 |
| Kurtz, TW | 1 |
| Varani, J | 1 |
| Robertshaw, H | 1 |
| Friedmann, PS | 2 |
| Shafiq, N | 1 |
| Gupta, M | 1 |
| Kumar, B | 1 |
| Sandhu, K | 2 |
| Krentz, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00395941] | Phase 2 | 40 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial[NCT02347501] | Phase 2 | 118 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | µg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | -0.2 |
| Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmHg (Median) |
|---|---|
| Sitagliptin | 4 |
| Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | 0.1 |
| Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 3 |
| Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 9.5 |
| Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | kg (Median) |
|---|---|
| Sitagliptin | -0.5 |
| Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Gliclazide | -1.12 |
| Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Sitagliptin | 3.41 |
| Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | -0.07 |
| Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 6 |
| Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
| Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
| Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PASI 50 | PASI 75 | PASI 90 | |
| Gliclazide | 1 | 0 | 0 |
| Sitagliptin | 1 | 0 | 0 |
5 reviews available for pioglitazone and Psoriasis
| Article | Year |
|---|---|
Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry.
Topics: Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Psoriasis | 2022 |
Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials.
Topics: Humans; Pioglitazone; Psoriasis; Publication Bias; Randomized Controlled Trials as Topic; Severity o | 2020 |
The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Pioglitazone; Psoriasis; Randomized Cont | 2020 |
Effects of antidiabetic drugs on psoriasis: A meta-analysis.
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatme | 2021 |
Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Combined Modality Therapy; Dermatologic Agents; Drug Therapy, Combination; Humans; Phototherapy; Pio | 2020 |
6 trials available for pioglitazone and Psoriasis
5 other studies available for pioglitazone and Psoriasis
| Article | Year |
|---|---|
Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Cholecalciferol; Coal Tar; Drug Therapy, Combination; Female; Humans | 2017 |
Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.
Topics: Aged; Cholagogues and Choleretics; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver | 2003 |
Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes.
Topics: Adult; Cell Division; Cell Movement; Cells, Cultured; Epidermal Cells; Fibroblasts; Humans; Hypoglyc | 2004 |
Pioglitazone: a promising therapy for psoriasis.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Humans; Male; Middle Aged; Pilot Projects; Piog | 2005 |
Type 2 diabetes, psoriasis and thiazolidinediones.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazon | 2006 |